Prostaglandin analogs signal detection by data mining in the FDA Adverse Event Reporting System database.

Author:

Contreras-Salinas Homero1,Romero-López María Soledad1,Olvera-Montaño Oscar1,Rodríguez-Herrera Lourdes Yolotzin1

Affiliation:

1. Laboratorios Sophia (Mexico)

Abstract

Abstract

Background: Adverse Events (AEs) which are not mentioned in the safety information label the any drug, are considered “unexpected” and must be regarded and analyzed as a safety signal. Prostaglandins cause effects on different cell types around the body, triggering diverse actions, and due to the analogy of an endogenous prostamida of the prostaglandin’s analogs, it is essential to identify the possible association that could cause the use of these drugs in ophthalmologic practice. This study aims to identify safety signals of ophthalmic prostaglandin analogs (PGAs) through data mining the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: A data mining search by proportional reporting ratio, reporting odds ratio, Bayesian confidence propagation neural network, information component 0.25, and Chi-squared for safety signals detection was conducted to the FAERS database for the following ophthalmic medications: latanoprost, travoprost, tafluprost, and bimatoprost for the identification AE with statistical associations. Results: Twelve preferred terms were statistically associated: diabetes mellitus, n=2; hypoacusis, n=2; malignant mediastinal neoplasm, n=1; blood immunoglobulin E increased, n=1; cataract, n=1; blepharospasm, n=1; full blood count abnormal, n=1; skin exfoliation, n=1; chest discomfort, n=1; and dry mouth, n=1. Conclusions: Of the twelve PTs analyzed, eight of them found information on the possible relationship due to the biological plausibility derived from information from previous research; for this reason, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk with its consequent minimization.

Publisher

Research Square Platform LLC

Reference50 articles.

1. Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors;Lusthaus JA;Expert Opin Emerg Drugs,2016

2. Prostaglandins in the eye: Function, expression, and roles in glaucoma;Doucette LP;Ophthalmic Genet,2017

3. The side effects of the prostaglandin analogues;Holló G;Expert Opin Drug Saf,2007

4. Kumari A. Chapter 16 - Prostaglandin Synthesis. In: Kumari ABT-SB, ed. Academic Press; 2018:85–87. https://doi.org/10.1016/B978-0-12-814453-4.00016-9.

5. Pfizer Laboratories/Food and Drug Administration. Xalatan- latanoprost. Accessed February 16., 2023. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4e73059-5ba0-4d73-9ea1-09d8d654e844&type=display.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3